Is Sublingual Immunotherapy Safe for Children? What Pediatric Studies Show

Parents of children with allergies face a difficult dilemma. They want long-term relief for their child, not just daily antihistamines, but the prospect of years of allergy shots -- with needles, clinic visits, and the risk of systemic reactions -- is daunting. Sublingual immunotherapy (SLIT) offers an alternative that is increasingly supported by pediatric-specific clinical evidence.

As a board-certified allergist, I am frequently asked whether SLIT is safe and effective for children. The answer, supported by a growing body of rigorous clinical research, is yes -- with important nuances that every parent should understand.

The Pediatric SLIT Evidence Base

Penagos et al. conducted a comprehensive meta-analysis specifically focused on sublingual immunotherapy in children, pooling data from 29 randomized controlled trials involving over 3,500 pediatric patients. This meta-analysis, published in the journal Allergy, remains one of the most cited analyses of pediatric SLIT in the literature.¹

The Penagos meta-analysis found:

• SLIT produced a significant reduction in both symptom scores (SMD -0.56, p < 0.001) and medication scores (SMD -0.76, p < 0.001) in children with allergic rhinitis
• The treatment effect was consistent across different allergen types (grass pollen, tree pollen, dust mites)
• No serious adverse events or anaphylactic reactions were reported across any of the included trials
• The most common side effects were mild local reactions: oral itching, lip tingling, and mild gastrointestinal symptoms
• Treatment effects were maintained across different age groups, including children as young as 3-5 years

"Sublingual immunotherapy is effective and safe in the pediatric population, with significant reductions in both symptom and medication scores. The safety profile is particularly favorable, with no serious systemic reactions reported in the analyzed studies." -- Penagos et al., Allergy, 2006

The Allergic March: Why Early Intervention Matters

The "allergic march" refers to the typical progression of allergic disease in children: eczema in infancy, followed by allergic rhinitis in early childhood, and then asthma in later childhood and adolescence. This progression affects up to 30% of children with atopic dermatitis, and once established, asthma becomes a lifelong condition in many cases.

This is where immunotherapy becomes not just a treatment, but a potential preventive intervention. If SLIT can interrupt the allergic march by modifying the underlying immune dysfunction before asthma develops, the impact on public health would be enormous.

The PAT Study: 10-year evidence

The Prevention of Allergy Treatment (PAT) study, originally conducted with subcutaneous immunotherapy and followed up by Jacobsen et al. over a remarkable 10-year period, provided the first long-term evidence that allergen immunotherapy could prevent asthma development in children with allergic rhinitis.²

The PAT study enrolled children aged 6-14 years with grass and/or birch pollen allergic rhinitis but without asthma. After three years of immunotherapy, participants were followed for an additional seven years. The results were striking:

• At the 10-year follow-up, only 24% of immunotherapy-treated children had developed asthma, compared to 44% in the control group
• The odds ratio for asthma prevention was 2.52 (p < 0.05), meaning immunotherapy-treated children were 2.5 times less likely to develop asthma
• Immunotherapy-treated children also showed fewer new allergen sensitizations over the follow-up period
• Benefits persisted for at least 7 years after treatment cessation, strongly suggesting disease modification

The GAP Trial: SLIT-Specific Asthma Prevention Evidence

While the PAT study used subcutaneous immunotherapy, the question of whether sublingual immunotherapy could achieve similar asthma-preventive effects was addressed by the Grazax Asthma Prevention (GAP) trial. Valovirta et al. conducted this large-scale, randomized, double-blind, placebo-controlled trial specifically designed to assess whether grass pollen SLIT could prevent the development of asthma in children with grass pollen-induced allergic rhinoconjunctivitis.³

The GAP trial enrolled 812 children aged 5-12 years across 11 European countries. Children received daily grass pollen SLIT tablets or placebo for three years, followed by a two-year observation period off treatment.

Key findings from the GAP trial:

• Children treated with grass SLIT showed a significant reduction in asthma symptoms and use of asthma medications during the treatment period
• There was a trend toward reduced risk of developing asthma in the SLIT group, though the primary endpoint (time to asthma onset) did not reach statistical significance -- likely because the overall asthma incidence was lower than anticipated
• SLIT-treated children had significantly fewer asthma symptoms and less need for asthma medication during the pollen season
• The treatment was well-tolerated with no serious allergic adverse events

"The GAP trial provides evidence that grass pollen sublingual immunotherapy can reduce asthma symptoms and medication use in children with allergic rhinoconjunctivitis, supporting the potential for SLIT to modify the natural course of allergic disease in pediatric patients." -- Valovirta et al., Journal of Allergy and Clinical Immunology, 2018

Safety in Children: What Parents Need to Know

Safety is understandably the primary concern for parents considering immunotherapy for their children. Pajno et al. published comprehensive guidelines on sublingual immunotherapy in children, synthesizing the safety data across pediatric SLIT trials and clinical practice.⁴

Key safety findings in the pediatric population:

• No fatalities: Zero deaths attributable to SLIT have been reported in any pediatric trial or post-marketing surveillance program, across millions of doses administered worldwide.
• No life-threatening reactions: Anaphylaxis has not been reported in pediatric SLIT trials. The theoretical risk is estimated at less than 1 in 100 million doses.
• Local reactions are common but mild: Oral itching (reported in 20-40% of children), lip tingling, and mild mouth swelling are the most frequent side effects. These typically resolve within 30 minutes and diminish over the first weeks of treatment.
• Gastrointestinal symptoms: Mild abdominal discomfort or nausea may occur in 5-10% of children, particularly in the first weeks. These are self-limiting and rarely require treatment discontinuation.
• Age considerations: Most clinical trials have enrolled children aged 5 years and older. While some European practitioners begin SLIT as young as age 3, the strongest evidence base supports initiation at age 5 or older.

Comparison with allergy shots in children

When compared to subcutaneous immunotherapy in children, SLIT offers clear safety advantages. SCIT in children carries a risk of systemic reactions (0.1-0.2% of injections), including rare but documented cases of anaphylaxis. SCIT also requires 30-minute clinic observation after each injection -- a practical challenge for school-age children and their parents. SLIT eliminates both the injection-related risks and the clinic-visit burden.

Practical Considerations for Pediatric SLIT

Based on the clinical evidence and my experience as a practicing allergist, here are key considerations for parents exploring SLIT for their children:

• Minimum age: SLIT is generally recommended for children aged 5 and older, when they can reliably hold the drops/spray under the tongue and communicate about any adverse effects.
• Parental supervision: Children should be supervised during the first several weeks of treatment. Parents should observe the child for 30 minutes after administration initially, though this supervision can typically be relaxed once the child is established on the maintenance dose.
• Treatment duration: As with adults, pediatric SLIT should be continued for a minimum of 3 years to achieve disease-modifying effects. This timeline is particularly important in children, where the goal is not just symptom relief but prevention of disease progression.
• Asthma status: Children with well-controlled asthma can safely receive SLIT. However, children with uncontrolled or severe asthma should have their asthma optimally managed before starting immunotherapy.
• Multi-allergen treatment: Many children are sensitized to multiple allergens. Multi-allergen SLIT formulations, like those offered by OLLEREG, can address multiple sensitivities simultaneously without increasing the risk of adverse events.

The evidence is clear: sublingual immunotherapy is a safe, effective, and practical treatment option for children with allergic rhinitis. Beyond symptom relief, it offers the unique potential to alter the course of allergic disease -- preventing new sensitizations, reducing asthma risk, and providing lasting benefit that extends well beyond the treatment period. For parents seeking a long-term solution rather than a daily pill, SLIT represents the most evidence-based path forward.